Trial Profile
A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Zibotentan (Primary)
- Indications Kidney disorders
- Focus Biomarker; Therapeutic Use
- Acronyms ZEBRA
- 30 Oct 2017 Status changed from recruiting to completed.
- 05 Oct 2015 Accrual to date is 19% according to United Kingdom Clinical Research Network.
- 07 Aug 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network.